Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 8/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | PYGL | P06737 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16349644 | 0.82 | KDM4E (0.55) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL5818325 | 0.79 | NPC1 (0.75) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| SCHEMBL7533561 | 0.75 | NPC1 (0.74) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| SCHEMBL8769590 | 0.75 | NPC1 (0.82) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| SCHEMBL9525511 | 0.74 | NPC1 (0.48) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| SCHEMBL7208136 | 0.74 | NPC1 (1.00) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| SCHEMBL29475123 | 0.74 | NPC1 (1.00) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| SCHEMBL22898907 | 0.73 | CYP2A6 (0.51) | NPC1RAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL468970 | 0.73 | MAOB (0.74) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| Hydrochloric Acid SCHEMBL16465542 | 0.73 | NPC1 (0.97) | NPC1RAB9ALMNASMN1; SMN2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034959-B2 | Methods of treating cancer with an antibody-drug conjugate | MEDAREX, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20090175888-A1 | METHODS OF TREATING CANCER WITH AN ANTIBODY-DRUG CONJUGATE | MEDAREX, INC. (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090175888-A1 | METHODS OF TREATING CANCER WITH AN ANTIBODY-DRUG CONJUGATE | PDIA5, CD38, DUT | NPC1 2474/4885RAB9A 2777/4885LMNA 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.